Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP
Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP is drawing significant interest across the industry.
FDA acknowledged that AURORA and BEACON provided sufficient evidence that bitopertin significantly lowers PPIX and that there is a strong mechanistic and biological plausibility supporting the use of the PPIX biomarker in protoporphyriaFDA indicated a need to see the results of the ongoing Phase 3 APOLLO study before making a decisionOngoing Phase 3 APOLLO study potential to serve as basis for traditional approval; topline data anticipated Q4 2026 WATERTOWN, Mass., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced that the U.S. Food and Drug Administration (FDA) today issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for bitopertin as a treatment for patients with erythropoietic protoporphyria (EPP). Bitopertin has been under review for accelerated approval and as part of the Commissioner’s National Priority Voucher (CNPV) pilot program.
Experts suggest this could influence future trends and innovation in the sector.
More updates are expected as the story develops.
Related Articles
- SolarPower Europe issues due diligence guide for PV-BESS
- Jammu & Kashmir’s Ranji Revolution: The Need for ‘Chaska’ of Victory and How J&K Shed the Underdog Label | EXCLUSIVE
- Review: Super-size video distractions at the Fort Worth Symphony gala
- DOH, Quezon City LGU team up to strengthen‘car
Source: Original →